CRISPR Therapeutics AG

CRSP: XNAS (USA)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
^^<LOCK|#<PLOCK|?tpL<<c

Crispr Earnings: Casgevy Sees Stronger Uptake as Early-Stage Pipeline Assets Make Progress

Crispr's gene therapy Casgevy, in partnership with Vertex Pharmaceuticals, is gaining traction, generating $54 million in fourth-quarter revenue and $116 million for the year. Crispr's early-stage pipeline is also making progress, but the firm ended the year with a net loss of $581 million.

Sponsor Center